Denosumab, sold under the brand names Prolia and Xgeva among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.[7][8]
Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.[9]
Denosumab is an inhibitor of RANKL (receptor activator of nuclear factor kappa-Β ligand),[7] which works by decreasing the development of osteoclasts, which are cells that break down bone. It was developed by the biotechnology company Amgen.[10]
^ ab"Regulatory Decision Summary for Jubbonti". Drug and Health Products Portal. 16 February 2024. Retrieved 1 April 2024.
^ ab"Regulatory Decision Summary for Wyost". Drug and Health Products Portal. 1 March 2024. Retrieved 1 April 2024.
^"Prolia- denosumab injection". DailyMed. 24 January 2024. Archived from the original on 7 June 2023. Retrieved 6 March 2024.
^"Xgeva- denosumab injection". DailyMed. 9 June 2020. Archived from the original on 13 April 2023. Retrieved 6 March 2024.
^Cite error: The named reference Prolia EPAR was invoked but never defined (see the help page).
^Cite error: The named reference Xgeva EPAR was invoked but never defined (see the help page).
^ abPageau SC (2009). "Denosumab". mAbs. 1 (3): 210–5. doi:10.4161/mabs.1.3.8592. PMC 2726593. PMID 20065634. Archived from the original on 8 March 2012. Retrieved 27 March 2011.
^McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. (February 2006). "Denosumab in postmenopausal women with low bone mineral density". The New England Journal of Medicine. 354 (8): 821–31. doi:10.1056/NEJMoa044459. PMID 16495394.
^Cite error: The named reference EMEA was invoked but never defined (see the help page).
^"Prolia (denosumab)". Products. Amgen. Archived from the original on 29 September 2015. Retrieved 6 May 2012.
Denosumab, sold under the brand names Prolia and Xgeva among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced...
some were given either 120 mg of denosumab or 4 mg of zoledronic acid. Patients who were given 120 mg of denosumab (in comparison to those who were given...
imperfecta to reduce the risk of broken bones. Combined teriparatide and denosumab increased BMD more than either agent alone and more than has been reported...
disparities exist. She has also appeared in commercials for Prolia, a brand of denosumab used in the treatment of osteoporosis. Danner was married to producer...
rhabdomyolysis, tumor lysis syndrome, and medications such as bisphosphonates or denosumab. Diagnosis should generally be confirmed by determining the corrected...
60-90% of patients who were treated for hypercalcemia of malignancy. Denosumab is a bone anti-resorptive agent that can be used to treat hypercalcemia...
metastases benefit from regular infusion of the bone-strengthening agents denosumab and the bisphosphonates; infusion every three months reduces the chance...
tested in conjunction with calcium and vitamin D to encourage bone health. Denosumab, a monoclonal antibody treatment RANKl inhibitor that targets the osteocyte...
and bone-targeting chemotherapeutic agents such as Bisphosphonates and Denosumab. Orthopedic interventions such as internal fixation or spinal decompression...
February 2024 adalimumab-ryvk/Simlandi adalimumab/Humira March 2024 denosumab-bbdz/Jubbonti denosumab/Prolia March 2024 denosumab-bbdz/Wyost denosumab/Xgeva...
baby's sex para-Dimethylaminobenzaldehyde, an organic chemical compound Denosumab, a drug for treating osteoporosis This disambiguation page lists articles...
they shrink tumors. Other bone modifying agents like zoledronic acid and denosumab can reduce prostate cancer bone pain, even though they have little effect...
(esomeprazole) (only in Japan; marketed by AstraZeneca elsewhere) Pralia (denosumab) (only available in Japan; also sold there as Ranmark) Tarlige (mirogabalin)...
one year, and the benefit was maintained after a second year of taking denosumab. In the other, one year of romosozumab followed by one year of alendronate...
in 2023. Products under development include biosimilars of omalizumab, denosumab, golimumab, aflibercept, vedolizumab, and pembrolizumab. In November 2022...
C; Cunningham, J; Ahuja, T; Richter, T; Kovacs, C (February 2012). "Denosumab, Raloxifene, and Zoledronic Acid for the Treatment of Postmenopausal Osteoporosis:...
needed] People with bone metastasis should receive bisphosphonates or denosumab to prevent skeletal related events (e.g. fractures, spinal cord compression...
breast cancer, it increases the risk of blood clots and strokes. While denosumab is effective at preventing fractures in women, there is not clear evidence...
Global Information
(what is this?) (verify)